Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transplant-eligible Patients”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT01513109
What this trial is testing

Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia

Who this might be right for
Acute Myelogenous LeukemiaMyeloid Leukemia in RemissionEffects of Immunotherapy
Jules Bordet Institute 20
Testing effectiveness (Phase 2)Study completedNCT01508312
What this trial is testing

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 66
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06963866
What this trial is testing

Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Xuzhou Medical University 60
Testing effectiveness (Phase 2)Looking for participantsNCT07106710
What this trial is testing

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China 30
Not applicableUnknownNCT03342677
What this trial is testing

Evaluation of Gd-EOB-DTPA MRI for Detection and Characterization of Liver Nodules in Cirrhotic Patients Undergoing Liver Transplantation and Potential Impact on Transplant Eligibility

Who this might be right for
Hepatocellular Carcinoma
University Health Network, Toronto 80
Testing effectiveness (Phase 2)Study completedNCT01795677
What this trial is testing

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

Who this might be right for
Myelofibrosis
French Innovative Leukemia Organisation 78
Early research (Phase 1)Study completedNCT05364424
What this trial is testing

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche 43
Early research (Phase 1)Study completedNCT01660750
What this trial is testing

A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma

Who this might be right for
Multiple Myeloma
Criterium, Inc. 29
Testing effectiveness (Phase 2)Study completedNCT02843074
What this trial is testing

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 53
Early research (Phase 1)Study completedNCT02513186
What this trial is testing

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Who this might be right for
Plasma Cell Myeloma
Sanofi 90
Large-scale testing (Phase 3)Active Not RecruitingNCT04096066
What this trial is testing

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

Who this might be right for
Multiple MyelomaNew Diagnosis Tumor
Fondazione EMN Italy Onlus 84
Post-approval studies (Phase 4)Looking for participantsNCT06370000
What this trial is testing

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality

Who this might be right for
Acute Myeloid Leukemia
Virginia Commonwealth University 12
Testing effectiveness (Phase 2)Looking for participantsNCT06252870
What this trial is testing

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Who this might be right for
Graft Versus Host DiseaseHematologic Malignancy
Nantes University Hospital 82
Testing effectiveness (Phase 2)Looking for participantsNCT05890352
What this trial is testing

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Who this might be right for
Grade 3b Follicular LymphomaHigh Grade B-Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements+3 more
SWOG Cancer Research Network 227
Early research (Phase 1)UnknownNCT02955810
What this trial is testing

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)

Who this might be right for
Multiple Myeloma
National University of Ireland, Galway, Ireland 18
Testing effectiveness (Phase 2)Study completedNCT02880228
What this trial is testing

Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Who this might be right for
Plasma Cell Myeloma
Mayo Clinic 11
Large-scale testing (Phase 3)Study completedNCT00722137
What this trial is testing

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
Millennium Pharmaceuticals, Inc. 487
Testing effectiveness (Phase 2)Active Not RecruitingNCT03896737
What this trial is testing

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 401
Large-scale testing (Phase 3)Looking for participantsNCT06918002
What this trial is testing

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Intergroupe Francophone du Myelome 824
Testing effectiveness (Phase 2)Ended earlyNCT04106700
What this trial is testing

Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Who this might be right for
Venous Thromboembolism
Instituto de Investigacion Sanitaria La Fe 60
Next Page